Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGK1 | P00558 | 3/20 | 0.51 |
| ▸ | PGK2 | P07205 | 3/20 | 0.51 |
| ▸ | THRA | P10827 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | PLK1 | P53350 | 1/20 | 0.41 |
| ▸ | SLC5A2 | P31639 | 8/20 | 0.39 |
| ▸ | SLC5A1 | P13866 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | F11 | P03951 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2868577 | 0.84 | THRA (0.50) | PGK1PGK2THRATHRBPLK1 | |
| SCHEMBL2869956 | 0.83 | PLK1 (0.40) | PGK1PGK2THRATHRBPLK1 | |
| SCHEMBL2859709 | 0.83 | PLK1 (0.40) | PGK1PGK2THRATHRBPLK1 | |
| SCHEMBL2864690 | 0.81 | CA2 (0.45) | THRATHRBPLK1SLC5A2SLC5A1 | |
| SCHEMBL2869183 | 0.75 | THRA (0.47) | PGK1PGK2THRATHRBPLK1 | |
| SCHEMBL2868572 | 0.75 | KDM4E (0.41) | SLC5A2SLC5A1CYP2C19ESR1ESR2 | |
| SCHEMBL2863551 | 0.74 | ALPG (0.44) | SMN1; SMN2 | |
| SCHEMBL2869960 | 0.74 | THRA (0.49) | THRATHRBPLK1CYP2C19SMN1; SMN2 | |
| SCHEMBL2864769 | 0.74 | SLC5A2 (0.45) | PGK1PGK2PLK1SLC5A2SLC5A1 | |
| SCHEMBL11304410 | 0.73 | ENPP2 (0.60) | PGK1PGK2PLK1CYP2C19SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691898-B2 | Phosphonic acid derivatives and the treating agents of diseases related hyperphosphatemia | KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) | 2010-04-06 | — | — | US | disclosed |
| US-20080119441-A1 | Phosphonic Acid Derivatives and the Treating Agents of Diseases Related Hyperphosphatemia | KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| CN-101072783-A | Phosphonic acid derivative and therapeutic agent for disease in which high phosphate level in blood participates | KOTOBUKI PHARMACEUTICAL CO LTD (JP) | 2007-11-14 | — | — | CN | disclosed |
| EP-1813620-A1 | PHOSPHONIC ACID DERIVATIVE AND THERAPEUTIC AGENT FOR DISEASE IN WHICH HIGH PHOSPHATE LEVEL IN BLOOD PARTICIPATES | Kotobuki Pharmaceutical Co., Ltd. (JP) | 2007-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119441-A1 | Phosphonic Acid Derivatives and the Treating Agents of Diseases Related Hyperphosphatemia | NR0B1, NR0B2, PTH1R | PGK1 2426/4885PGK2 1970/4885THRA 582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.